Product Details
Clinically proven extract for the relief of symptoms of acute bronchitis and acute sinusitis.
Key Benefits:
Helps reduce recovery time and symptoms of acute bronchitis
AUST-R complementary medicine
Children’s doses* for acute bronchitis
Well-tolerated and suitable for family members over 2 years old with acute bronchitis*
Convenient drop dosage
*Children under the age of 6 years should only be treated with Kaloba after previous consultation with a doctor.
Well-tolerated and effective for family members over 2 years old with acute bronchitis. Convenient drop dosage.
How to use
Acute bronchitis
Adults and adolescents over the age of 12 years:
Take 30 drops (1.35 ml) 3 times a day
Children aged between 6-12 years:
Take-20 drops (0.9 ml) 3 times a day
Children aged between 2-5 years:
Give 10 drops (0.45 ml) 3 times a day
Acute sinusitis
Adults take 60 drops (2.7 ml) 3 times a day
Always read the label. Use only as directed. If symptoms persist see your healthcare professional. Vitamin supplements may only be of assistance if the dietary vitamin intake is inadequate. All reasonable efforts have been made to ensure that ingredient listings for products displayed on this website are up to date, accurate and complete.
Please check ingredient listings for products before use or check in store.
Ingredients
Active ingredient per 1 mL: Pelargonium sidoides extract equiv. to 91 mg dry root
Warnings
Kaloba should not be used in children under 2 years of age
Children under the age of 6 years should only be treated with Kaloba after previous consultation with your doctor
Use during pregnancy or breast feeding is not recommended without first consulting with your doctor or pharmacist
Contains alcohol
Treatment duration should not exceed 1 week for acute bronchitis and 3 weeks for acute sinusitis
Consult your doctor immediately if the condition does not improve within one week, if you have fever that lasts for several days or in the case of shortness of breath or if you cough up bloody sputum
Reviews
There are no reviews yet.